The management of neuropathic ulcers of the foot in diabetes by shock wave therapy

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Moretti, Biagio ^a,b   Notarnicola, Angela ^a   Maggio, Giulio ^a   Moretti, Lorenzo ^a   Pascone, Michele ^a   Tafuri, Silvio ^a   Patella, Vittorio ^a  

^a UNIVERSITY OF BARI   (Italy)

^b SITOD   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; EPITHELIZATION; EXTRACORPOREAL LITHOTRIPSY; FEMALE; FOOT ULCER; HUMAN; INTERMETHOD COMPARISON; MALE; RANDOMIZED CONTROLLED TRIAL; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING; ANGIOGENESIS; BLOOD VESSEL; DIABETIC NEUROPATHY; EPITHELIUM CELL; FOOT; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; STATISTICS; TIME; TREATMENT OUTCOME; ULTRASOUND; ULTRASOUND THERAPY; VASCULARIZATION; WOUND INFECTION;

AGED; BLOOD VESSELS; DIABETIC FOOT; DIABETIC NEUROPATHIES; EPITHELIAL CELLS; FEMALE; FOOT; FOOT ULCER; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONIC THERAPY; ULTRASONICS; WOUND HEALING; WOUND INFECTION;

EID: 67650690628     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-54     Document Type: Article

References (52)

1. Foot ulcers in the diabetic patient, prevention and treatment. SC Wu VR Driver JS Wrobel DG Armstrong, Vasc Health Risk Manag 2007 3 1 65 76 17583176 (Pubitemid 46860717)
2. The diabetic foot: the scope of the problem. AJ Boulton L Vileikyte, J Fam Pract 2000 49 Suppl 11 S3 8
3. Epidemiology of foot ulcers and amputations in the diabetic foot. GE Reiber, The Diabetic Foot St. Louis: Mosby, J Bowker H, Pfeifer MA, 2001 13 32
4. Changing perspectives in diabetic foot ulcer management. CN Dang AJ Boulton, Int J Low Extrem Wounds 2003 2 4 12 10.1177/1534734603002001002 15866821
5. Guidelines for diabetic foot care: recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. MS Pinzur MP Slovenkai E Trepman NN Shields Diabetes Committee of American Orthopaedic Foot and Ankle Society, Foot Ankle Int 2005 26 113 19 15680122
6. Preventing foot ulcers in patients with diabetes. N Singh DG Armstrong BA Lipsky, JAMA 2005 293 217 28 10.1001/jama.293.2.217 15644549
7. The epidemiology of diabetic foot problems. GE Reiber, Diabet Med 1996 13 S6 S11 8741821
8. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. DJ Fernando EA Masson A Veves AJ Boulton, Diabetes Care 1991 14 8 11 10.2337/diacare.14.1.8 1991444
9. First ray joint limitation, pressure, and ulceration of the first metatarsal head in diabetes mellitus. JA Birke D Franks JG Foto, Foot Ankle 1995 16 277 84 7633584
10. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. LA Lavery RP Wunderlich JL Tredwell, Diabetes Res Clin Pract 2005 70 31 7 10.1016/j.diabres.2005.02.010 16126121
11. Role of neuropathy and high foot pressures in diabetic foot ulceration. RG Frykberg LA Lavery H Pham C Harvey L Harkless A Veves, Diabetes Care 1998 21 1714 19 10.2337/diacare.21.10.1714 9773736
12. Lengthening of the Achilles tendon in diabetic patients who are at high risk for ulceration of the foot. DG Armstrong S Stacpoole-Shea H Nguyen LB Harkless, J Bone Joint Surg (Am) 1999 81A 535 8
13. The diabetic foot. H Van Damme R Limet, Rev Med Liege 2005 60 516 25 16035320
14. The insensitive foot (including leprosy). PW Brand, Disorders of the Foot and Ankle Philadelphia: Saunders, Jahss M, 1991 2170 5
15. Biomechanical aspects of diabetic foot disease: aetiology, treatment, and prevention. PR Cavanagh JS Ulbrecht GM Caputo, Diabet Med 1996 13 Suppl 1 S17 22 8741823
16. Foot ulcers in the diabetic patient, prevention and treatment. SC Wu VR Driver JS Wrobel DG Armstrong, Vasc Health Risk Manag 2007 3 1 65 76 17583176 (Pubitemid 46860717)
17. The diabetic foot. PW Brand, Diabetes mellitus, theory and practice New York: Medical Examination Publishing, Ellenberg M, Rifkin H, 1983 803 28
18. The measurement of pressure under the foot. T Duckworth RP Betts CI Franks J Burke, Foot and Ankle 1982 3 130
19. The importance of abnormal foot pressure and gait in causation of foot ulcers. AJM Boulton, The foot in diabetes Chilchester: John Wiley and Sons, Connor H, Boulton AJM, Ward JD, 1987 11 26
20. Methods of treating plantar ulcers. JA Birke A Novick SL Graham WC Coleman DM Brasseaux, Phys Ther 1991 71 116 22 1989007
21. Biomechanical aspects of diabetic foot disease: aetiology, treatment, and prevention. PR Cavanagh JS Ulbrecht GM Caputo, Diabet Med 1996 13 Suppl 1 S17 22 8741823
22. Is there a critical level of plantar foot pressure to identify patients at risk for neuropathic foot ulceration? DG Armstrong EJ Peters KA Athanasiou LA Lavery, J Foot Ankle Surg 1998 37 303 7 10.1016/S1067-2516(98)80066-5 9710782
23. The description and classification of diabetic foot lesions. WJ Jeffcoate RM Macfarlane EM Fletcher, Diabet Med 1993 10 676 679 8403832 (Pubitemid 23246789)
24. Foot care in patients with diabetes mellitus (Position Statement). American Diabetes Association, Diabetes Care 1996 19 Suppl 1 S23 S24
25. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. MJ Young JL Breddy A Veves AJM Boulton, Diabetes Care 1994 16 557 560 10.2337/diacare.17.6.557 (Pubitemid 24161977)
26. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. JT Wieman JM Smiell Y Su, Diabetes Care 1998 21 822 827 10.2337/diacare.21.5.822 9589248
27. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: a pilot, randomized, double-blind, placebo-controlled study. JL Richard C Parer-Richard JP Daures S Clouet D Vannereau J Bringer M Rodier C Jacob M Comte-Bardonnet, Diabetes Care 1995 18 64 69 10.2337/diacare.18.1.64 7698050
28. Use of dermagraft, a culture d human dermis, to treat diabetic foot ulcers. GD Gentzkow SD Iwasaki KS Hershon M Mengel JJ Prendergast JJ Ricotta DP Steed S Lipkin, Diabetes Care 1996 19 350 354 10.2337/diacare.19.4.350 8729158 (Pubitemid 26115458)
29. The Diabetic Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. DL Steed, J Vasc Surg 1995 21 71 79 10.1016/S0741-5214(95)70245-8 7823364
30. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. DL Steed, J Vasc Surg 1995 21 71 8 10.1016/S0741-5214(95)70245-8 7823364
31. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. A Gough M Clapperton N Rolando AV Foster J Philpott-Howard ME Edmonds, Lancet 1997 350 9081 855 9 10.1016/S0140-6736(97) 04495-4 9310604
32. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. VM Donaghue JS Chrzan BI Rosenblum JM Giurini GM Habershaw A Veves, Adv Wound Care 1998 11 114 19 9729942
33. Adjuncts to preparing wounds for closure: hyperbaric oxygen, growth factors, skin substitutes, negative pressure wound therapy (vacuum-assisted closure). HW Hopf LM Humphrey N Puzziferri JM West CE Attinger TK Hunt, Foot Ankle Clin 2001 6 661 82 10.1016/S1083-7515(02)00008-6 12134577
34. The acutely infected diabetic foot is not adequately evaluated in an inpatientsetting. GW Edelson DG Armstrong LA Lavery G Caicco, Arch Intern Med 1996 156 2373 2378 10.1001/archinte.156.20.2373 8911244
35. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. DJ Margolis J Kantor J Santanna BL Strom JA Berlin, Arch Dermatol 2000 136 12 1531 5 10.1001/archderm.136.12.1531 11115166
36. Acoustic cavitation: a possible consequence of biomedical uses of ultrasound. RE Apfel, Br J Cancer Suppl 1982 5 140 6 6950749
37. Surface acoustic cavitation understood via nanosecond electrochemistry. Part III: Shear stress in ultrasonic cleaning. E Maisonhaute C Prado PC White RG Compton, Ultrason Sonochem 2002 9 6 297 303 10.1016/S1350-4177(02)00089-5 12404794
38. Medical applications and bioeffects of extracorporeal shock waves. M Delius, Shock Waves 1994 4 55 72 10.1007/BF01418569
39. MR imaging of plantar fasciitis: edema, tears, and occult marrow abnormalities correlated with outcome. RP Grasel ME Schweitzer AM Kovalovich D Karasick K Wapner P Hecht D Wander, Am J Roentgenol 1999 173 699 701 (Pubitemid 29395295)
40. Low-energy extracorporeal shock wave therapy for painful heel: aprospective controlled single-bind study. JD Rompe C Hopf B Nafe R Burger, J Orthop Trauma Surg 1996 115 75 79 10.1007/BF00573445
41. An overview of shock wave therapy in musculoskeletal disorders. CJ Wang, Chang Gung Med J 2003 26 4 220 32 12846521
42. Use of extracorporeal shock waves in the treatment of pseudarthrosis, tendinopathy and other orthopedic diseases. G Haupt, J Urol 1997 158 1 4 11 10.1097/00005392-199707000-00003 9186313
43. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. T Nishida H Shimokawa K Oi H Tatewaki T Uwatoku K Abe Y Matsumoto N Kajihara M Eto T Matsuda H Yasui A Takeshita K Sunagawa, Circulation 2004 110 19 3055 61 10.1161/01.CIR.0000148849. 51177.97 15520304
44. Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. T Uwatoku K Ito K Abe K Oi T Hizume K Sunagawa H Shimokawa, Coron Artery Dis 2007 18 5 397 404 10.1097/MCA.0b013e328089f19b 17627190
45. Extracorporal shock wave may enhance skin flap survival in an animal model. R Meirer FS Kamelger GM Huemer S Wanner H Piza-Katzer, Br J Plast Surg 2005 58 1 53 7 10.1016/j.bjps.2004.04.027 15629167
46. Shock wave therapy reduces necrotic flap zones and induces VEGF expression in animal epigastric skin flap model. R Meirer A Brunner M Deibl M Oehlbauer H Piza-Katzer FS Kamelger, J Reconstr Microsurg 2007 23 4 231 6 10.1055/s-2007-981506 17530616
47. Extracorporeal shock wave enhanced extended skin flap tissue survival via increase of topical blood perfusion and associated with suppression of tissue pro-inflammation. YR Kuo WS Wu YL Hsieh FS Wang CT Wang YC Chiang CJ Wang, J Surg Res 2007 143 2 385 92 10.1016/j.jss.2006.12.552 17720194
48. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. W Schaden R Thiele C Kölpl M Pusch A Nissan CE Attinger ME Maniscalco-Theberge GE Peoples EA Elster A Stojadinovic, J Surg Res 2007 143 1 1 12 10.1016/j.jss.2007.01.009 17904157
49. Antibacterial effects of extracorporeal shock waves. L Gerdesmeyer C von Eiff C Horn M Henne M Roessner P Diehl H Gollwitzer, Ultrasound Med Biol 2005 31 1 115 9 10.1016/j.ultrasmedbio.2004.08.022 15653238
50. Extracorporeal shock wave therapy ameliorates hindlimb ischemia in rabbits. K Oi Y Fukumoto K Ito T Uwatoku K Abe T Hizume H Shimokawa, Tohoku J Exp Med 2008 214 2 151 8 10.1620/tjem.214.151 18285673
51. New Guidelines for ESWT. R Tiele, Neswletter ISMST 2009 5 1 20
52. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. R Saggini A Figus A Troccola V Cocco A Saggini N Scuderi, Ultrasound Med Biol 2008 34 8 1261 71 10.1016/j.ultrasmedbio.2008.01.010 18394777